 The purpose of this study is to evaluate the safety of an additional 28 weeks of treatment with pegsunercept for subjects who have completed treatment in a previous double-blind study 20000201 or 20000198. In addition, this study will evaluate the efficacy and the feasibility of subject self-administration on an outpatient basis. 